Characteristics of familial and non-familial melanoma in Australia

Melanoma Research

Volumn 8, Issue 5, 1998, Pages 459-464

  Ang, C G ^a   Kelly, J W ^a,b   Fritschi, L ^b   Dowling, J P ^a,c  

^a Dermatology Unit   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c NONE   (Australia)

Author keywords

Dysplastic naevus; Familial melanoma; Multiple melanoma; Multiple naevi

Indexed keywords

ARTICLE; AUSTRALIA; CANCER RISK; CANCER SUSCEPTIBILITY; DYSPLASTIC NEVUS; HUMAN; MAJOR CLINICAL STUDY; MELANOCYTIC NEVUS; MELANOMA; PRIORITY JOURNAL; RISK ASSESSMENT;

EID: 0031740556     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008390-199810000-00011     Document Type: Article

References (28)

1. Greene MH, Fraumeni JF Jr. The hereditary variant of malignant melanoma. In: Clark WH Jr, Mastrangelo MJ, Goldman LI, eds. Human Malignant Melanoma. New York: Grune and Stratton, 1979: 139-166.
2. Wallace DC, Beardmore GL, Exton LA. Familial malignant melanoma. Ann Surg 1973; 177: 15-20.
3. Kopf AW, Hellman LJ, Rogers GS, et al. Familial malignant melanoma. JAMA 1986; 256: 1915-1919.
4. Grange F, Chompret A, Guilloud-Bataille M, et al. Comparison between familial and nonfamilial melanoma in France. Arch Dermatol 1995; 131: 1154-1159.
5. Petty EM, Bolognia JL, Bale AE, Yang Feng T. Cutaneous malignant melanoma and atypical moles associated with a constitutional rearrangement of chromosomes 5 and 9. Am J Med Genet 1993; 45(1): 77-80.
6. Cannon-Albright LA, Goldgar DE, Meyer LJ, et al. Assignment of a locus for familial melanoma to chromosome 9p13-p22. Science 1992; 258: 1148-1152.
7. Nancarrow DJ, Mann GJ, Holland EA, et al. Confirmation of chromosome 9p linkage in familial melanoma. Am J Hum Genet 1993; 53: 936-942.
8. Hussussian CJ, Struewing JR Goldstein AM, et al. Germline p16 mutations in familial melanoma. Nature Genet 1994; 8: 15-21.
9. Kamb A, Shattuck-Eidens D, Eeles R, et al. Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus. Nature Genet 1994; 8: 23-26.
10. Holland EA, Beaton SC, Becker TM, et al. Analysis of the p16 gene. CDKN2, in 17 Australian melanoma kindreds. Oncogene 1995; 11: 2289-2294.
11. Mackie RM. Melanoma prevention and early detection Br Med Bull 1995; 15: 570-583.
12. Balch CM, Murad TM, Soong SJ, Ingalls AL, Halpern NH, Maddox WA. A multifactorial analysis of melanoma: prognostic histopathologic features comparing Clarks and Breslow's staging methods. Ann Surg 1978; 188: 732-742.
13. Veronesi U, Cascinelli N, Adamus J, et al. Thin stage 1 primary cutaneous malignant melanoma: comparison of excision with margins of 1 or 3 cm. N Engl J Med 1988; 318: 1159-1162.
14. Anderson DE. Clinical characteristics of the genetic variety of cutaneous melanoma in man. Cancer 1971; 28: 721-725.
15. Barnhill RL, Roush GC, Titus-Ernstoff L, Ernstoff MS, Duray PH, Kirkwood JM. Comparison of nonfamilial and familial melanoma. Dermatology 1992; 184: 2-7.
16. Aitken JP, Green AC, Maclennan R, Youl P, Martin NG. The Queensland Familial Melanoma Project: study design and characteristics of participants. Melanoma Res 1996; 6: 155-165.
17. Pathak MA, Fitzpatrick TB, Greiter F, et al. Preventive treatment of sunburn, dermatoheliosis, and skin cancer with sun protective agents. In Fitzpatrick TB, Eisen AZ, Wolff K, Freedberg IM, Austin KF, eds. Dermatology in General Medicine, 3rd edn. New York: McGraw-Hill, 1987: 1507-1522.
18. Kelly JW, Crutcher WA, Sagebiel RW. Clinical diagnosis of dysplastic melanocytic naevi. J Am Acad Dermatol 1986; 14: 1044-1052.
19. Aitken JF, Dutfy DL, Green A, Youl P, Maclennan R, Martin NG. Heterogeneity of melanoma risk in families of melanoma patients. Am J Epidemiol 1994; 140: 961-973.
20. Clark WH Jr, Reimer RR, Greene MH, Ainsworth AA, Mastrangelo MJ. Origin of familial malignant melanomas from heritable melanocytic lesions. Arch Dermatol 1978; 114: 732.
21. Elder DE, Goldman LI, Goldman SC, Greene MH, Clark WH Jr. The dysplastic naevus syndrome a phenotypic association of sporadic cutaneous malignant melanoma. Cancer 1980; 46: 1787-1794.
22. Holly EA, Kelly JW, Shpall SN, Chiu SH. Number of melanocytic naevi as a major risk faclor for malignant melanoma. J Am Acad Dermatol 1987; 17: 459-468.
23. Tucker MA, Halpern A, Holly EA, et al. Clinically recognized dysplastic naevi. JAMA 1997; 277(18): 1439-1444.
24. Greene MH, Clark WH, Tucker MA, Kraemer KH, Elder DE, Fraser MC. High risk of malignant melanoma in melanoma prone families with dysplastic naevi. Ann Intern Med 1985; 102: 458-465.
25. Lucchina LC, Barnhill RL, Duke DM, Sober AJ. Familial cutaneous melanoma. Melanoma Res 1995; 5: 413-418.
26. Kefford RE, Salmon J, Shaw HM, Donald JA, McCarthy WH. Hereditary melanoma in Australia. Cancer Genet Cytogenet 1991; 51: 45-55.
27. Duke D, Castresena J, Lucchina L, et al. Familial cutaneous melanoma and two mutational event modeling. Cancer 1993; 72: 3229-3243.
28. Ford D, Bliss JM, Swerdlow AJ, et al. Risk of cutaneous melanoma associated with a family history of the disease. Int J Cancer 1995; 62: 377-381.